Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer: drug cocktail trial targets stage IV

NCT ID NCT03819465

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times

Summary

This study tests whether adding new cancer drugs to the immunotherapy durvalumab, with or without chemotherapy, can safely control advanced lung cancer. It involves 175 adults with stage IV non-small cell lung cancer who have not had prior treatment for their metastatic disease. The goal is to find better first-line options to manage the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Iowa City, Iowa, 52242, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15212, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Salzburg, 5020, Austria

  • Research Site

    Vienna, 1140, Austria

  • Research Site

    Edegem, 2650, Belgium

  • Research Site

    Bialystok, 15-027, Poland

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Gdansk, 80-214, Poland

  • Research Site

    Grudziądz, 86-300, Poland

  • Research Site

    Lodz, 90-302, Poland

  • Research Site

    Olsztyn, 10-357, Poland

  • Research Site

    Tomaszów Mazowiecki, 97-200, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Wroclaw, 53-413, Poland

  • Research Site

    Krasnoyarsk, 660133, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Saint Petersburg, 191014, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 110-744, South Korea

  • Research Site

    Barcelona, 08025, Spain

  • Research Site

    Barcelona, 8003, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Kaohsiung City, 807, Taiwan

  • Research Site

    Taichung, 402, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Chiang Mai, 50200, Thailand

  • Research Site

    Hat Yai, 90110, Thailand

Conditions

Explore the condition pages connected to this study.

METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)